Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK5533524 · 1 trial · 1 indication
ORR is defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
| Arm | Type | Description |
|---|---|---|
| Part 1a: GSK5533524 Dose Escalation & Backfill | EXPERIMENTAL | - |
| Part 1b: GSK5533524 Dose Expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GSK5533524 | DRUG | GSK5533524 will be administered. |
Inclusion Criteria: * Is at least 18 years of age or the legal age of consent * Has histologically or cytologically confirmed advanced/metastatic solid tumor that is refractory to standard therapy, for which no standard treatment is available, or who is intolerant to established standard of care th...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
GSK5533524 is an investigational small molecule being developed for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is currently being studied in adult participants with advanced solid tumors as part of a first-in-human clinical trial.
GSK5533524 is being developed by GSK plc, a global biopharma company listed on the London Stock Exchange under the ticker GSK. The company is conducting a Phase 1 clinical trial to evaluate the safety and preliminary activity of the drug in patients with advanced solid tumors.
GSK5533524 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being tested in clinical trials to assess its safety and preliminary activity in patients with advanced solid tumors.
GSK5533524 is being studied in a single Phase 1 trial with the identifier NCT07438782. This first-in-human study is investigating the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors. The trial is currently recruiting participants.
The GSK5533524 Phase 1 clinical trial is being conducted in multiple countries, including the United States, Canada, Finland, Japan, Spain, and the United Kingdom. The study enrolls adults aged 18 years and older with advanced solid tumors, and it is currently recruiting participants.